TearSolutions, Inc. Appoints Louis M Alpern, MD, MPH, FACS, FICS to its Board of Directors
April 03, 2024 06:00 ET
|
TearSolutions, Inc.
CHARLOTTESVILLE, Va., April 03, 2024 (GLOBE NEWSWIRE) -- TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED)...
TearSolutions, Inc. Appoints Robert Dempsey to its Board of Directors
November 01, 2023 06:00 ET
|
TearSolutions, Inc.
CHARLOTTESVILLE, Va., Nov. 01, 2023 (GLOBE NEWSWIRE) -- TearSolutions, Inc., a privately held biotech company developing potentially disruptive therapies for the treatment of Dry Eye Disease (DED)...
TearSolutions Expands and Establishes Advisory Boards and Strengthens Leadership Team
March 07, 2023 06:00 ET
|
TearSolutions, Inc.
CHARLOTTESVILLE, Va., March 07, 2023 (GLOBE NEWSWIRE) -- TearSolutions, Inc. a privately held clinical-stage ophthalmic biopharmaceutical company focused on developing a potentially disruptive...
TearSolutions, Inc. Announces Outcome of Type C Meeting with FDA and Next Steps in the Development of Lacripep™
February 14, 2022 05:00 ET
|
TearSolutions, Inc.
CHARLOTTESVILLE, Va., Feb. 14, 2022 (GLOBE NEWSWIRE) -- TearSolutions, Inc. (“the Company”), a privately held developer of a replacement therapy for the treatment of Dry Eye Disease (DED) called...